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OBJECTIVE: Typically, bone metastasis causes osteolytic and osteoblastic lesions resulting from the interactions
of tumor cells with osteoclasts and osteoblasts. In addition to these interactions, tumor tissues may grow inside
bones and cause mass lesions. In the present study, we aimed to demonstrate the negative impact of a tumor
mass in a large cohort of patients with bone metastatic cancer.
METHODS: Data from 335 patients with bone metastases were retrospectively reviewed. For the analysis, all
patients were divided into three subgroups with respect to the type of bone metastasis: osteolytic, osteoblastic,
or mixed. The patients were subsequently categorized as having bone metastasis with or without a tumor mass,
and statistically significant differences in median survival and 2-year overall survival were observed between
these patients (the median survival and 2-year overall survival were respectively 3 months and 16% in patients
with a tumor mass and 11 months and 26% in patients without a tumor mass; po0.001).
RESULTS: According to multivariate analysis, the presence of bone metastasis with a tumor mass was found to
be an independent prognostic factor (p=0.011, hazard ratio: 1.62, 95% confidence interval: 1.11–1.76). Bone
metastasis with a tumor mass was more strongly associated with osteolytic lesions, other primary diseases
(except for primary breast and prostate cancers), and spinal cord compression.
CONCLUSION: Bone metastasis with a tumor mass is a strong and independent negative prognostic factor for
survival in cancer patients.
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’ INTRODUCTION
Bone metastasis is the most frequent complication of cancer,
occurring in up to 70% of patients with breast or prostate cancer
and in approximately 15–30% of patients with carcinoma of the
lung, colon, stomach, bladder, rectum, thyroid, or kidney (1).
Although the exact incidence of bone metastasis remains
unknown, this type of metastasis is an attractive area of study
given its high prevalence in cancer patients.
Bone metastases develop as a result of interactions between
tumor cells and bone cells. Cancer cells can induce various
metastatic bone lesions through different mechanisms that
depend on the primary disease, and two types of metastatic
bone lesions have been described (2,3). The first is an osteolytic
lesion that progresses with bone resorption as a result of
osteoclast activation; the second is an osteoblastic lesion that
triggers bone formation and osteoblastic cell activation. These
two types of lesions may be present concomitantly in certain
patients (mixed type) following stimulation of the two different
types of bone cells. Alternatively, the tumor itself may grow
inside the bone tissue and destroy the bone directly (4). These
mass lesions may cause an increase in complications (e.g., spinal
cord compression, pathologic fracture) due to metastasis-related
bone destruction and suggest the presence of a significant tumor
burden. Examples of computerized tomography images of
osteolytic lesions, osteoblastic lesions, and bone metastasis with
a tumor mass are shown in Figure 1.
Although the duration of survival varies according to the
primary tumor, bone metastases are usually incurable (5).
General treatment procedures for patients with bone
metastasis include bisphosphonate administration, che-
motherapy, and palliative radiation therapy. However,
responses to these treatment modalities are relatively poor,
and the patient’s quality of life is generally impaired.DOI: 10.6061/clinics/2015(08)01
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Prognosis may vary among patients depending on factors
such as the primary disease type, age, the patient’s
performance status, the metastatic interval, and the number
of metastatic sites (6,7). Nevertheless, these factors are not
particularly helpful with respect to decision making in
routine clinical practice. Moreover, data on both the
prognostic impact of the mechanism type on bone metastasis
and the additional role of tumor masses in these patients are
lacking.
Therefore, we designed a retrospective analysis to evaluate
the impact of bone metastasis-related tumor mass on patient
survival. We also evaluated differences in the response to
radiation therapy, in complications, and in the pain response
in our cohort according to the type of metastasis.
’ MATERIALS AND METHODS
This study was conducted at the Department of Radiation
Oncology at Cumhuriyet University Hospital in Sivas,
Turkey, in accordance with the principles of the Declaration
of Helsinki. A total of 335 cancer patients with bone
metastasis who were admitted to the department between
2007 and 2013 were evaluated retrospectively.
All patients were treated with palliative radiotherapy and
bisphosphonate. During the treatment period, all patients
were examined by a radiation oncologist immediately before
and 1 month after radiotherapy. The physical examination
findings as well as body weight; Eastern Cooperative
Oncology Group (ECOG) performance scores; and histo-
pathological, radiological, and laboratory data (alkaline
phosphatase [ALP] and calcium levels) were recorded. The
patients’ survival data were obtained from hospital records,
and patients lost to follow-up were contacted to obtain
information about their condition. Survival was defined as
the time between the date of the first detection of bone
metastasis and the date of last contact or death.
The cancer type was classified based on the primary site:
head and neck, lung, breast, prostate, gastrointestinal
system, genitourinary system, or other. Prior to palliative
radiotherapy, each patient’s performance status was scored
according to the ECOG scoring system (8). Weight loss was
defined as loss of 410% of body weight in 1 month.
Bone metastasis was revealed by computerized tomogra-
phy or magnetic resonance imaging and was confirmed by
bone scintigraphy and positron emission tomography.
All patients were divided into three subgroups with
respect to the type of bone metastasis: osteolytic, osteo-
blastic, or mixed type. All patients were subsequently
recategorized into two groups: bone metastasis with or
without a tumor mass.
Pain intensity was evaluated using visual analog scales in
139 (41%) of the cases (9). Patients were routinely asked to
rate their pain intensity by placing a mark on a 10-mm visual
analog scale at the start of radiotherapy and at 1 month after
radiotherapy. This scaling system was used to evaluate the
intensity of pain only in the radiotherapy-affected region.
The response to radiotherapy was determined by calculating
the difference between the pain intensity on the visual analog
scale before and 1 month after the initiation of radiotherapy.
Statistical Package for Social Sciences (SPSS) for Windows
14.0 (SPSS, Inc., Chicago, IL, USA) was used for the statistical
analysis. For descriptive statistics, the mean, standard
deviation, frequency, and median were used. Categorical
data were compared statistically using the chi-square test or
Fisher’s exact test. Survival rates were calculated according
to the Kaplan-Meier method. A multivariate analysis (Cox
regression analysis) was used to evaluate independent risk
factors affecting survival. P-values p0.05 were accepted as
statistically significant.
’ RESULTS
The study group comprised 234 (70%) men and 101 (30%)
women. The median age at the time of cancer diagnosis was
59 years (range, 21–82 years). The primary disease distribu-
tion was as follows: lung cancer in 107 (32%) patients, breast
cancer in 64 (19%), prostate cancer in 62 (19%), gastro-
intestinal system tumors in 40 (12%), genitourinary system
tumors in 20 (6%), head and neck tumors in 11 (3%), and
tumors in other organs in 31 (9%).
Osteolytic bone metastasis was observed in 99 (30%)
patients, whereas 155 (46%) had osteoblastic bone metastasis,
and 71 (21%) had mixed-type bone metastasis. Ten (3%)
patients had bone metastasis and only a tumor mass,
without any other lesions; these 10 patients were excluded
when categorizing the patients with respect to the type of
bone lesion (i.e., osteolytic, osteoblastic, or mixed). Bone
metastasis with a tumor mass was present in 73 (22%) cases.
Eleven (3%) patients had a single bone metastatic lesion, and
324 (97%) had two or more lesions. The 11 patients with
single bone lesions had no metastases in other organs. The
locations and frequencies of bone metastases were as follows:
vertebral column metastasis in 283 (84%) patients, pelvic
bone metastasis in 246 (73%), long bone metastasis in 189
(56%), costal metastasis in 189 (56%), and skull metastasis in
63 (19%).
Figure 1 - Types of bone metastasis (white arrows). A) Osteolytic metastasis. B) Osteoblastic metastasis. C) Bone metastasis with a tumor
mass.
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Spinal cord compression was observed in 20 patients, or
7% of all patients with vertebral column metastases (N: 283),
whereas 49 (15%) patients had pathologic fractures, 26 (8%)
had neurological deficits, and 16 (5%) had hypercalcemia.
Surgical interventions were performed for pathologic frac-
tures in 19 (39%) patients with pathologic fractures (N: 49).
The types of bone metastasis with respect to primary
disease were as follows. Among patients with lung cancer, 42
(39%) had osteolytic lesions, 44 (41%) had osteoblastic
lesions, 19 (18%) had mixed lesions, and 2 (2%) had bone
metastases with only tumor masses. For patients with breast
cancer, 22 (34%), 19 (30%), and 22 (34%) had osteolytic,
osteoblastic, and mixed lesions, respectively; 1 (2%) had a
bone metastasis with only a tumor mass. Osteolytic,
osteoblastic, and mixed lesions developed in 2 (3%), 53
(86%), and 7 (11%), respectively, patients with prostate
cancer. Regarding patients with gastrointestinal system
tumors, 9 (22%), 18 (45%), and 11 (28%) had osteolytic,
osteoblastic, and mixed lesions, respectively, and 2 (5%)
showed bone metastases with only tumor masses. Among
patients with genitourinary system tumors, 8 (40%), 5 (25%),
and 5 (25%) had osteolytic, osteoblastic, and mixed lesions,
respectively, with 2 (10%) exhibiting bone metastases with
only tumor masses. The incidence of osteolytic, osteoblastic,
and mixed lesions was 2 (18%), 5 (46%), and 2 (18%),
respectively, for the patients with head and neck tumors; 2
(18%) had bone metastases with only tumor masses.
Bone metastasis with a tumor mass was observed more
frequently in patients with osteolytic lesions than in those
with other bone lesions. Spinal cord compression was
observed more frequently in cases of bone metastasis with
a tumor mass compared to cases without a tumor mass;
when occurring in the latter, the compression was mostly
due to compression fracture, as observed for osteolytic
metastases, or to new bone formation, as observed in
osteoblastic lesions. However, serum ALP levels were higher
in patients without tumor masses. In addition, bone
metastases with tumor masses were observed less frequently
in patients with primary breast or prostate cancer compared
with patients with other primary diseases, such as lung or
gastrointestinal system tumors. With respect to pathologic
fractures, pain severity, and responses to radiotherapy, no
differences were observed between cases of bone metastases
with tumor masses and cases of other bone metastases
(Table 1).
The median survival duration was 10 months (range, 1–
147 months), and the 1- and 2-year survival rates were 46%
and 24%, respectively. The median survival duration was 3
months and the 1- and 2-year survival rates were 28% and
16%, respectively, among patients who had bone metastases
with tumor masses and 11 months and 50% and 26%,
respectively, in patients who had bone metastasis without
tumor masses. The survival curves of the patients with or
without a tumor mass are shown in Figure 2. Univariate
Table 1 - Comparison of features associated with bone metastases with or without tumor masses.
Bone metastasis without a tumor mass
(N: 262, 78%)
Bone metastasis with a tumor mass
(N: 73, 22%)
p-value
Type of bone metastasis
Osteolytic 60 (61) 39 (39) o0.001
Osteoblastic 151 (97) 4 (3)
Mixed 51 (72) 20 (28)
Bone metastasis with only a tumor mass - 10 (100)
Primary disease
Lung 80 (75) 27 (25) o0.001
Breast 57 (89) 7 (11)
Prostate 58 (94) 4 (6)
Gastrointestinal system 27 (68) 13 (32)
Genitourinary system 13 (65) 7 (35)
Head and neck 7 (64) 4 (36)
Other 20 (65) 11 (35)
Serum ALP1 level
p129 U/L 137 (75) 47 (25) 0.028
4129 U/L 119 (84) 23 (16)
Serum calcium level
p10.6 mg/dL 246 (79) 64 (21) 0.103
410.6 mg/dL 10 (63) 6 (37)
Spinal cord compression
No 219 (83) 44 (17) o0.001
Yes 6 (30) 14 (70)
Pathologic fracture
No 228 (80) 58 (20) 0.079
Yes 34 (69) 15 (31)
Surgery
No 249 (79) 67 (21) 0.213
Yes 13 (68) 6 (32)
Severity of pain
Mild 12 (86) 2 (14) 0.312
Moderate 25 (66) 13 (34)
Severe 57 (65) 30 (35)
Response to radiotherapy
No 23 (64) 13 (36) 0.306
Yes 71 (69) 32 (31)
Abbreviation: 1ALP, alkaline phosphatase
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analyses showed that the survival duration after metastasis
was affected by the presence of bone metastasis with a tumor
mass as well as by gender, weight loss, performance status,
serum ALP and calcium levels, primary disease, bone
metastasis type, number of bone lesions, the presence of
extraosseous metastasis, and the disease-free interval. The
prognostic factors that affected survival time after the
development of bone metastasis are shown in Table 2.
Multivariate analyses revealed that the presence of bone
metastasis with a tumor mass as well as gender, weight loss,
primary disease, type of bone metastasis, and serum ALP
and calcium levels were independent prognostic factors that
affected survival. The independent prognostic factors that
affected the duration of survival after the development of
bone metastasis are shown in Table 3.
’ DISCUSSION
The prevalence of bone metastasis is higher in advanced-
stage cancers. Patients diagnosed with bone metastasis
usually have incurable disease, though the survival duration
does vary based on the primary disease. Accordingly, it is
very important to determine prognostic factors once a
diagnosis of bone metastasis has been made. The present
study investigated the prognostic and clinical importance of
bone metastasis with a tumor mass and found that this
feature was an apparently strong negative prognostic factor
for survival. The higher incidence of these metastases in
association with osteolytic lesions might have contributed to
this result, as the presence of osteolytic lesions was found to
be a poor prognostic factor in a multivariate analysis. In
addition, growth of the tumor itself inside the bone might
indicate a larger tumor burden, which might also contribute
to a shorter survival duration. Given the soft tissue
component of bone metastasis with a tumor mass, spinal
cord compression was observed more frequently in these
patients; nonetheless, the presence of these lesions did not
increase the pain intensity or affect the response to
radiotherapy.
Certain researchers have studied prognostic factors in
patients with bone metastases. In a study of 350 patients with
skeletal metastases, Katagiri et al. (6) reported that the
patient’s performance status, the primary lesion site, the
presence of multiple skeletal metastases, the presence of
visceral or cerebral metastases, and a history of previous
chemotherapy were important prognostic factors. Van der
Linder et al. (7) reported a median survival time of 7 months
for 342 patients with vertebral metastases, and Karnofsky
stated that the performance score, the primary tumor type,
and absence of visceral metastasis were significant predictors
of survival. In the present study, female gender, the presence
of osteoblastic and/or mixed lesions, and primary breast or
prostate cancer were considered to be good prognostic
predictors. In contrast, the presence of bone metastasis with a
tumor mass as well as male gender, weight loss, primary
lung cancer, the presence of osteolytic lesions, and elevated
ALP and calcium levels were found to be poor prognostic
predictors. Poor performance in a single-variable analysis, a
disease-free interval of o2 years, the presence of extraoss-
eous metastasis, and multiple bone lesions were also poor
prognostic factors.
Circulating metastatic cells in blood become entrapped by
the bone marrow spongiosum. Cancerous bone undergoes
secondary lytic or blastic changes (10), and the type of bone
metastasis is determined by these changes. In the literature,
osteolytic lesions have been reported to be more frequent in
breast cancer cases, whereas osteoblastic lesions are observed
in cases of prostate cancer. In the present study, osteoblastic
lesions (46%) were more frequently observed in the overall
patient population; similar to the findings of other studies,
osteolytic lesions were more frequent in patients with breast
cancer, with osteoblastic lesions being more common in
patients with prostate cancer. In terms of the conventional
classification of bone metastases, the presence of a tumor
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Figure 2 - Survival curves of patients with or without a tumor mass.
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mass was significantly more frequent among osteolytic
lesions (62%). The frequencies of bone metastasis with a
tumor mass were low among patients with breast or prostate
cancer and similar among those with other types of cancer.
Specifically, 25–36% of patients with other types of cancer
(non-breast or prostatic) had bone lesions with tumor
masses.
Bone metastases are associated with a particular set of
complications, and the frequency of these complications
varies depending on the features of the metastatic lesions.
For example, pathologic fractures and spinal cord compres-
sion are encountered more frequently with osteolytic lesions,
as these lesions cause bone destruction (2,11). It is rational to
expect that bone metastases with tumor masses would
present more complications; indeed, spinal cord compression
was more frequent among cases of bone metastasis with a
tumor mass in the current study. However, an elevated
serum ALP level was more frequently observed in cases of
bone metastasis without a tumor mass. In terms of
pathologic fractures, serum calcium levels, surgical interven-
tion, pain severity, and responses to radiotherapy, no
differences were observed between patients with bone
metastasis with a tumor mass and those with other types
of bone metastases.
The survival duration in patients with bone metastases
varied quite significantly depending on the primary disease,
and it is reported that the duration is generally longer for
patients with breast or prostate cancer than for those with
other types of cancer (1,7,6,11). Ahn et al. (12) reported a
median survival time of 55.2 months among 110 breast
cancer patients with only bone metastases. In contrast,
survival durations as short as 5–7 months were reported
among patients with lung cancer and bone metastases
(11,13,14). In our study, the longest survival durations were
observed in patients with breast cancer, followed by those
with prostate cancer (median survival durations of 18
months and 15 months, respectively); conversely, the
survival times of patients with other cancers were relatively
short.
Many studies have reported that patients with single bone
lesions in the absence of metastases in other organs have a
longer survival duration relative to those with multiple bone
metastases (15-17). In a study of 42 patients with solitary
bone metastases, Hoshi et al. (15) reported a median survival
duration of 30 months and a 1-year survival rate of 76.5%. In
the present study, the 11 patients with single bone lesions
had a median survival duration of 32 months and a 1-year
survival rate of 68%. The survival durations were shorter
Table 2 - Prognostic factors affecting patient survival after the development of bone metastasis, as determined by univariate survival
analysis.
No. of patients 1-year survival (%) 2-year survival (%) Median survival (months) p-value
Bone metastasis with tumor mass
No 262 50 26 11 *o0.001
Yes 73 28 16 3
Gender
Male 234 39 17 8 o0.001
Female 101 61 42 17
Weight loss
No 248 53 27 12 o0.001
Yes 87 24 12 5
ECOG PS1
ECOG0-1 168 55 30 13 o0.001
ECOG2 and higher 167 36 17 7
Serum ALP2 level
p129 U/L 184 50 29 12 0.004
4129 U/L 142 39 16 9
Serum calcium level
p10.6 mg/dL 310 46 24 10 0.027
410.6 mg/dL 16 - - 3
Primary disease
Lung 107 27 10 5 o0.001
Breast 64 72 47 18
Prostate 62 69 31 15
Gastrointestinal system 40 24 6 5
Genitourinary system 20 20 10 5
Head and neck 11 9 - 3
Type of bone metastasis
Osteolytic 99 29 14 4 0.004
Osteoblastic 155 53 26 12
Mixed 71 49 26 12
Number of bone lesions
1 lesion 11 68 68 32 0.040
X2 lesions 324 44 22 10
Extraosseous metastasis
No 176 51 27 12 0.032
Yes 159 40 18 8
Disease-free interval
o24 months 259 41 20 9 0.026
X24 months 76 61 35 18
Abbreviations: 1ECOG PS, Eastern Cooperative Oncology Group performance status; 2ALP, alkaline phosphatase
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among the patients with osteolytic lesions compared with
patients with osteoblastic or mixed lesions. Moreover,
patients with bone metastases with tumor masses had
significantly shorter survival durations compared with those
with bone metastases without tumor masses (median
survival durations of 3 months and 11 months, respectively;
1-year survival rates of 28% and 50%, respectively).
Two major limitations of the present study were its
retrospective design and its heterogeneous study population.
We believe that studies of more specific groups would yield
more significant results.
The presence of bone metastasis with a tumor mass
appeared to be a strong negative prognostic factor and was
associated with a higher incidence of spinal cord compression.
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